Accessibility Menu
InMed Pharmaceuticals logo

InMed Pharmaceuticals(NASDAQ) INM

Market Cap$5.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-38%
1 Month+6%
$1.65
-3.51%
-0.06Today
InMed Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.642026-07-27
InMed Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.89%USD 1.522026-07-20
1 month+6.49%USD 1.542026-06-26
3 month+133.95%USD 0.702026-04-28
Year to date+54.72%USD 1.062025-12-31
1 year-37.88%USD 2.642025-07-25
3 year-92.74%USD 22.602023-07-28
5 year-99.88%USD 1,355.002021-07-28
Since inception-99.96%USD 4,257.002014-05-06

InMed Pharmaceuticals Financials at a Glance

Market Cap

$5.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.02M

Net Income (TTM)

-$9.91M

EPS (TTM)

-$2.58

P/E Ratio

-0.66

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$1.65

Volume

335,650

Open

$1.66

Previous Close

$1.64

Daily Range

$1.60 - $1.80

52-Week Range

$0.58 - $2.71

Estimated Earnings Date

Sep 18, 2026

INM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InMed Pharmaceuticals

InMed develops medicines using rare cannabinoids, which are compounds found in cannabis plants. Its products aim to help people with skin, eye, and nerve conditions. The company also supplies these compounds to other businesses in health and wellness.

What’s in the Medicine Cabinet? (Products and Services)

  • BayMedica Commercial (100% revenue): Sells rare, non-intoxicating cannabinoids as raw materials to health and wellness companies.
  • INM-755: A topical cream for a rare skin disorder, studied in clinical trials for patients with epidermolysis bullosa.
  • INM-088: An eye drop candidate in preclinical testing for glaucoma, a disease that damages the optic nerve.
  • INM-405: A pain management drug in early development, targeting chronic pain conditions.
  • INM-901 and INM-089: Experimental drugs for Alzheimer’s disease and age-related macular degeneration, both in preclinical stages.
  • IntegraSyn: A technology platform for making pharmaceutical-grade cannabinoids efficiently for research and commercial use.

Growth Spurts and Strategic Moves

  • Formed a research partnership with BayMedica for new cannabinoid therapies.
  • Expanded product pipeline with INM-901 (Alzheimer’s) and INM-089 (macular degeneration) in 2024-2025.
  • Launched IntegraSyn manufacturing platform, improving cannabinoid production efficiency since 2023.
  • Secured equity financing agreements in 2024-2025 to support ongoing research and operations.

Why InMed Is a Bit Different

InMed combines drug development with commercial sales of rare cannabinoids, serving both pharmaceutical and wellness markets. Its IntegraSyn platform allows flexible, cost-effective production of high-purity compounds. The company’s patent portfolio covers new drug candidates and manufacturing methods.

Five Things You Need to Know

  • Revenue was $1M in QQ1 2026, down 11.4% from QQ1 2025.
  • Gross profit was $403,159 in QQ1 2026, down 18.3% year-over-year.
  • Net loss was $-2M in QQ1 2026, nearly unchanged from QQ1 2025.
  • All sales in QQ1 2026 came from BayMedica Commercial, not drug development.
  • Cash and short-term investments totaled $4.7M as of March 31, 2025.

Bottom Line

InMed has shifted from pure research to a dual model, selling rare cannabinoids while advancing new drug candidates. The company faces ongoing financial challenges but continues to diversify its pipeline and revenue sources.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Eric A. Adams

Website

www.inmedpharma.com

Headquarters

Vancouver, BC V6C 1B4, CA

INM Financials

Key Financial Metrics (TTM)

Gross Margin

30.44%

Operating Margin

-246.78%

Net Income Margin

-246.41%

Return on Equity

-72.72%

Return on Capital

-41.00%

Return on Assets

-108.52%

Earnings Yield

-1.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.31M

Volume

335.65K

Avg. Volume

2.52M

Financials (TTM)

Gross Profit

$1.22M

Operating Income

-$9.93M

EBITDA

-$9.23M

Operating Cash Flow

-$9.01M

Capital Expenditure

$9.49

Free Cash Flow

-$9.01M

Cash & ST Invst.

$5.20M

Total Debt

$420.15K

InMed Pharmaceuticals Performance Analysis

InMed Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 1,089,435N/A
20232023-06-30USD 4,135,561279.6%
20242024-06-30USD 4,597,73011.2%
20252025-06-30USD 4,942,6337.5%
InMed Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3040.9%
Q12025-09-30-37.0%
Q22025-12-310.5%
Q32026-03-31-100.0%
InMed Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -16,582.70N/A
20232023-06-30USD -64.92-99.6%
20242024-06-30USD -20.14-69.0%
20252025-06-30USD -8.36-58.5%
InMed Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3037.1%
Q12025-09-30-35699.2%
Q22025-12-31-61.2%
Q32026-03-3199.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$5.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$435.92K

N/A

Employees

13

N/A

Net Income

-$2.97M

-39.9%

EBITDA

-$2.66M

-33.5%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$5.20M

-22.0%

Total Debt

$420.15K

-65.2%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$30.77K

-94.8%

Short Term Debt

$389.38K

-36.3%

Return on Assets

-1.09%

N/A

Return on Invested Capital

-1.43%

N/A

Free Cash Flow

-$1.76M

-6.0%

Operating Cash Flow

-$1.76M

-6.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SILOSilo Pharma, Inc.
$4.40-1.57%
GLMDGalmed Pharmaceuticals Ltd.
$0.53+2.75%
GNPXGenprex, Inc.
$7.74-0.96%
CNSPCNS Pharmaceuticals, Inc.
$5.07-3.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About INM

What is the current price of InMed Pharmaceuticals?

InMed Pharmaceuticals is trading at $1.64 per share.

What is the 52-week range for InMed Pharmaceuticals?

Over the past 52 weeks, InMed Pharmaceuticals has traded between $0.58 and $2.71.

How much debt does InMed Pharmaceuticals have?

As of the most recent reporting period, InMed Pharmaceuticals reported total debt of $420.15K.

How much cash does InMed Pharmaceuticals have on hand?

InMed Pharmaceuticals reported $5.16M in cash and cash equivalents in its most recent financial results.

What is InMed Pharmaceuticals’s dividend yield?

InMed Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services